CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 343 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01917656
NCT01917656Phase 4Completed
CompareCT.gov

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Aug 7, 2013·Updated Aug 24, 2017

In Brief

A Phase 4 clinical trial evaluating liraglutide, metformin, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 343 participants across 41 sites in 7 countries.

Detailed Summary

This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAlgeria, India, Israel, Lebanon, Malaysia, South Africa, United Arab Emirates
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 7, 2013
Enrollment StartJan 9, 2014
Primary CompletionSep 1, 2014
Study CompletionSep 4, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.9 years ago

Interventions

liraglutidedrug

1.8 mg administered subcutaneously (s.c., under the skin) once daily

metformindrug

Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged

sulphonylureadrug

Subjects will continue on their pre-trial SU tablet treatment, doses unchanged